The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

BackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.Method...

Full description

Bibliographic Details
Main Authors: Hao-Ran Zheng, Ai-Min Jiang, Huan Gao, Na Liu, Xiao-Qiang Zheng, Xiao Fu, Zhi-Ping Ruan, Tao Tian, Xuan Liang, Yu Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/full
_version_ 1811266327046782976
author Hao-Ran Zheng
Hao-Ran Zheng
Ai-Min Jiang
Huan Gao
Na Liu
Xiao-Qiang Zheng
Xiao Fu
Zhi-Ping Ruan
Tao Tian
Xuan Liang
Yu Yao
author_facet Hao-Ran Zheng
Hao-Ran Zheng
Ai-Min Jiang
Huan Gao
Na Liu
Xiao-Qiang Zheng
Xiao Fu
Zhi-Ping Ruan
Tao Tian
Xuan Liang
Yu Yao
author_sort Hao-Ran Zheng
collection DOAJ
description BackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.MethodsPathologically confirmed ES-SCLC patients receiving anlotinib plus platinum-etoposide chemotherapy as the first-line treatment were enrolled in this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. The Cox regression analyses were employed to investigate the independent prognostic factors for OS and PFS of these individuals.ResultsIn total, 58 patients were included in this study. The median PFS was 6.0 months [95% confidence interval (CI): 3.5-8.5], and the median OS was 10.5 months (95%CI 8.7-12.3). Thirty-four patients achieved partial response (PR), 18 patients achieved stable disease (SD), and 6 patients achieved progressive disease (PD). The ORR and DCR were 58.6% and 89.6%. The main treatment-related adverse reactions were generally tolerated. Myelosuppression (44.8%) was the most common adverse reaction, followed by hypertension (41.4%), fatigue (34.5%), gastrointestinal reaction (32.7%), and hand-foot syndrome (24.1%). Multivariate analysis showed that post-medication hand-foot syndrome [PFS 8.5 vs. 5.5 months, Hazards Ratio (HR)=0.23, 95%CI 0.07-0.72, P =0.012] was the independent predictor of PFS, and hypertension (OS 15.9 vs. 8.3 months, HR=0.18, 95%CI 0.05-0.58, P =0.005) was the independent predictor of OS.ConclusionAnlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ES-SCLC appears to be effective and well-tolerated in the real-world. Well-designed large-scale prospective studies are urgently needed in the future to verify our findings.
first_indexed 2024-04-12T20:40:50Z
format Article
id doaj.art-bcffe294e47c490fa68083e505bce920
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-04-12T20:40:50Z
publishDate 2022-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-bcffe294e47c490fa68083e505bce9202022-12-22T03:17:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.894835894835The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world studyHao-Ran Zheng0Hao-Ran Zheng1Ai-Min Jiang2Huan Gao3Na Liu4Xiao-Qiang Zheng5Xiao Fu6Zhi-Ping Ruan7Tao Tian8Xuan Liang9Yu Yao10Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, Xi’an No.3 Hospital, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ChinaBackgroundPatients with extensive-stage small-cell lung cancer (ES-SCLC) have high recurrence rates and bleak prognosis. This multicenter real-world study aimed to explore the efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment of ES-SCLC.MethodsPathologically confirmed ES-SCLC patients receiving anlotinib plus platinum-etoposide chemotherapy as the first-line treatment were enrolled in this retrospective study. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions. The Cox regression analyses were employed to investigate the independent prognostic factors for OS and PFS of these individuals.ResultsIn total, 58 patients were included in this study. The median PFS was 6.0 months [95% confidence interval (CI): 3.5-8.5], and the median OS was 10.5 months (95%CI 8.7-12.3). Thirty-four patients achieved partial response (PR), 18 patients achieved stable disease (SD), and 6 patients achieved progressive disease (PD). The ORR and DCR were 58.6% and 89.6%. The main treatment-related adverse reactions were generally tolerated. Myelosuppression (44.8%) was the most common adverse reaction, followed by hypertension (41.4%), fatigue (34.5%), gastrointestinal reaction (32.7%), and hand-foot syndrome (24.1%). Multivariate analysis showed that post-medication hand-foot syndrome [PFS 8.5 vs. 5.5 months, Hazards Ratio (HR)=0.23, 95%CI 0.07-0.72, P =0.012] was the independent predictor of PFS, and hypertension (OS 15.9 vs. 8.3 months, HR=0.18, 95%CI 0.05-0.58, P =0.005) was the independent predictor of OS.ConclusionAnlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ES-SCLC appears to be effective and well-tolerated in the real-world. Well-designed large-scale prospective studies are urgently needed in the future to verify our findings.https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/fullsmall cell lung canceranlotinibchemotherapyreal-world dataefficacysafety
spellingShingle Hao-Ran Zheng
Hao-Ran Zheng
Ai-Min Jiang
Huan Gao
Na Liu
Xiao-Qiang Zheng
Xiao Fu
Zhi-Ping Ruan
Tao Tian
Xuan Liang
Yu Yao
The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
Frontiers in Oncology
small cell lung cancer
anlotinib
chemotherapy
real-world data
efficacy
safety
title The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
title_full The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
title_fullStr The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
title_full_unstemmed The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
title_short The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
title_sort efficacy and safety of anlotinib combined with platinum etoposide chemotherapy as first line treatment for extensive stage small cell lung cancer a chinese multicenter real world study
topic small cell lung cancer
anlotinib
chemotherapy
real-world data
efficacy
safety
url https://www.frontiersin.org/articles/10.3389/fonc.2022.894835/full
work_keys_str_mv AT haoranzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT haoranzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT aiminjiang theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT huangao theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT naliu theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xiaoqiangzheng theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xiaofu theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT zhipingruan theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT taotian theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xuanliang theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT yuyao theefficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT haoranzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT haoranzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT aiminjiang efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT huangao efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT naliu efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xiaoqiangzheng efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xiaofu efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT zhipingruan efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT taotian efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT xuanliang efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy
AT yuyao efficacyandsafetyofanlotinibcombinedwithplatinumetoposidechemotherapyasfirstlinetreatmentforextensivestagesmallcelllungcancerachinesemulticenterrealworldstudy